Search clinical trials for: Recombinant COVID-19 vaccine (Sf9 cell)

Total 378 results

WestVac Biopharma Co., Ltd.

Active, not recruiting

Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)

COVID-19

China
WestVac Biopharma Co., Ltd.
WestVac Biopharma (Guangzhou) Co., Ltd.

Recruiting

A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

COVID-19

China
WestVac Biopharma Co., Ltd.

Active, not recruiting

Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102)

COVID-19

China
WestVac Biopharma Co., Ltd.

Not yet recruiting

A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination

COVID-19
WestVac Biopharma Co., Ltd.
West China Hospital

Completed

A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

COVID-19 | SARS-CoV-2 Infection

China
WestVac Biopharma Co., Ltd.

Completed

Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

COVID-19 | SARS-CoV-2 Infection

Philippines
WestVac Biopharma Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster

COVID-19 | SARS-CoV-2 Infection

Mexico
WestVac Biopharma Co., Ltd.

Completed

A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)

COVID-19 | SARS-CoV-2 Pneumonia

China
Jiangsu Province Centers for Disease Control and...
West China Hospital

Withdrawn

Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells)

COVID-19

China
WestVac Biopharma Co., Ltd.
West China Hospital

Not yet recruiting

Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents

COVID-19

China
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Lanzhou Institute of Biological... and other collaborators

Recruiting

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

Coronavirus Infections | COVID-19 Pneumonia

United Arab Emirates
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Lanzhou Institute of Biological...

Active, not recruiting

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

Coronavirus Infections | COVID-19 Pneumonia

United Arab Emirates
WestVac Biopharma Co., Ltd.
West China Hospital

Active, not recruiting

A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)

COVID-19

Philippines, Indonesia, Kenya, Mexico, Nepal
WestVac Biopharma Co., Ltd.

Not yet recruiting

A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination

COVID-19
Jiangsu Province Centers for Disease Control and...
West China Hospital

Completed

A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)

COVID-19

China
National Vaccine and Serum Institute, China
China National Biotec Group Company Limited; Beijing Institute of Biological... and other collaborators

Recruiting

A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)

COVID-19

United Arab Emirates
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
First Affiliated Hospital Bengbu Medical College

Completed

Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)

COVID-19

China
China National Biotec Group Company Limited
The University of Hong Kong; Beijing Institute of Biological Products Co Ltd.; Wuhan Institute of Biological Products Co., Ltd

Active, not recruiting

Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above (COVID-19)

COVID-19

Hong Kong
Jiangsu Rec-Biotechnology Co., Ltd.

Completed

Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)

COVID-19

United Arab Emirates
Jiangsu Rec-Biotechnology Co., Ltd.

Completed

Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) (ReCOV)

COVID-19

Philippines
CanSino Biologics Inc.

Withdrawn

A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine

COVID-19
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Hunan Provincial Center for...

Active, not recruiting

Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above (COVID-19)

COVID-19

China
Sinovac Biotech (Hong Kong) Limited

Completed

Immunogenicity and Safety Study of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain

COVID-19

China
Sinovac Biotech (Colombia) S.A.S.
Sinovac Life Sciences Co., Ltd.

Not yet recruiting

Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated

COVID-19

Colombia
Jiangsu Rec-Biotechnology Co., Ltd.

Completed

Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)

COVID-19

Russian Federation, Nepal
University Health Network, Toronto
Canadian Institutes of Health Research (CIHR); Samuel Lunenfeld Research Institute... and other collaborators

Active, not recruiting

SafeTy and Efficacy of Preventative CoVID Vaccines (STOPCoV)

Vaccine Response | COVID-19 Virus Infection

Canada
Canadian Immunization Research Network
Massachusetts General Hospital; CHU de Quebec-Universite Laval; McGill University... and other collaborators

Active, not recruiting

Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity (MOSAIC)

COVID-19

Canada
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.

Active, not recruiting

A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated (COVID-19)

Covid19

China
CNBG-Virogin Biotech (Shanghai) Ltd.

Recruiting

A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

SARS-CoV-2 Infection

China
Hospital Moinhos de Vento
Pfizer; Universidade Federal do Paraná; Inova Medical

Completed

A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil

Covid19

Brazil
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above

COVID-19

China
Huntington Memorial Hospital

Completed

Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients

Covid19 | Vaccine Reaction

United States
The Immunobiological Technology Institute (Bio-Manguinhos)...

Recruiting

Study of Immunogenicity Equivalence of a Homologous Third Dose of Covid-19 (Recombinante) Vaccine

COVID-19

Brazil
CNBG-Virogin Biotech (Shanghai) Ltd.
Shulan (Hangzhou) Hospital

Recruiting

A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

SARS-CoV-2 Infection

China
The Immunobiological Technology Institute (Bio-Manguinhos)...

Active, not recruiting

Immunogenicity Study of the Covid-19 (Recombinante) Vaccine With a 4 or 8 Week Interval Between the First Doses.

COVID-19

Brazil
Jiangsu Province Centers for Disease Control and...

Completed

Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine

COVID-19

China
Sinovac Research and Development Co., Ltd.

Completed

Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above

COVID-19

China
Jiangsu Rec-Biotechnology Co., Ltd.
Iqvia Pty Ltd

Completed

Safety, Reactogenicity and Immunogenicity Study of ReCOV

Covid19

New Zealand
Laboratorios Hipra, S.A.

Completed

Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)

Covid19 | SARS CoV 2 Infection

Spain
Zhongnan Hospital
Institute of Biotechnology, Academy of Military Medical Sciences, PLA of...

Recruiting

A Clinical Trial on Booster Immunization of Two COVID-19 Vaccines Constructed From Different Technical Routes

COVID-19

China
Centre Hospitalier Universitaire de Saint Etienne
Sanofi Pasteur, a Sanofi Company; Bioster, a.s.

Completed

Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19 (COVIMMUNAGE)

Covid19

France
The First Affiliated Hospital of Soochow University

Withdrawn

Clinical Study on the Impact of Covid-19 Vaccine on Allogeneic Hematopoietic Stem Cell Transplantation

Hematologic Diseases

China
Yisheng Biopharma (Singapore) Pte. Ltd.

Active, not recruiting

A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.

Covid-19 Vaccine

United Arab Emirates, Philippines
ModernaTX, Inc.

Active, not recruiting

An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)

COVID-19

United States
Sinovac Research and Development Co., Ltd.

Withdrawn

Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong

COVID-19

China
Zhejiang Provincial Center for Disease Control...

Recruiting

Sequential Immunization With Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Health Adults Based on 3 Doses Inactivated COVID-19 Vaccine

Immunogenicity and Safety of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine Using for Sequential Immunization

China
PT Bio Farma
Fakultas Kedokteran Universitas Indonesia; Faculty of Medicine Universitas... and other collaborators

Completed

Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine

COVID-19

Indonesia
Methodist Health System

Completed

COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose

COVID-19 | COVID-19 Pneumonia

United States
National Institute of Allergy and Infectious Diseases...
National Heart, Lung, and Blood Institute (NHLBI); University of Copenhagen; US... and other collaborators

Completed

Vaccination for Recovered Inpatients With COVID-19 (VATICO)

Covid19

United States, Spain, Uganda, Nigeria, Singapore, Switzerland
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Shulan (Hangzhou) Hospital

Active, not recruiting

A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above (COVID-19)

COVID-19

China

Search clinical trials for: Recombinant COVID-19 vaccine (Sf9 cell)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations